Share this post on:

Product Name: FLT3 (phospho Tyr969) antibody [T.602.6]
Applications: WB
Predicted Target Size:
Positive Controls:
Form Supplied: Liquid
Concentration:
Purification:
Full Name: fms-related tyrosine kinase 3
Background: This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.
Synonyms: CD135 antigen, FL cytokine receptor, FLT-3, FLT3 receptor tyrosine kinase, OTTHUMP00000214829, STK-1, fetal liver kinase 2, fms-like tyrosine kinase 3, growth factor receptor tyrosine kinase type III, stem cell tyrosine kinase 1, tyrosine-protein kinase receptor FLT3
Cellular Localization:
CAS NO: 857290-04-1
KB-R7943 (mesylate)
Host: Rabbit
Clonality: Monoclonal
Isotype: IgG
Immunogen: Synthetic phosphopeptide corresponding to the sequence surrounding Tyr969 of human FLT3.
Antigen Species: Human
Species Reactivity: Human, Mouse
Conjugation: Unconjugated
Storage Buffer: 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 ug/ml BSA, 50% glycerol and less than 0.02% sodium azide.
Storage Instruction:
Notes: For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Specificity:
PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21497180?dopt=Abstract

Share this post on: